EF Hutton analyst Michael King maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $851 to $853.
If You Invested $1,000 When Jim Farley Became Ford CEO, Here’s How Much You’d Have Now
In October 2020, Ford welcomed its 11th chief executive officer in its 117-year history and the stock has performed well since the CEO switch.